Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing

BMC Medical Genomics

Volumn 10, Issue 1, 2017, Pages

  Cheng, Donavan T ^a,b   Prasad, Meera ^a   Chekaluk, Yvonne ^c   Benayed, Ryma ^a   Sadowska, Justyna ^a   Zehir, Ahmet ^a   Syed, Aijazuddin ^a   Wang, Yan Elsa ^a   Somar, Joshua ^a   Li, Yirong ^a   Yelskaya, Zarina ^a   Wong, Donna ^a   Robson, Mark E ^a   Offit, Kenneth ^a   Berger, Michael F ^a   Nafa, Khedoudja ^a   Ladanyi, Marc ^a   Zhang, Liying ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ILLUMINA INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ATM PROTEIN; CHECKPOINT KINASE 2; PROTEIN P53; TUBERIN; VON HIPPEL LINDAU PROTEIN; APC PROTEIN, HUMAN; ATM PROTEIN, HUMAN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; VHL PROTEIN, HUMAN;

APC GENE; ARTICLE; ATM GENE; CANCER SUSCEPTIBILITY; CHEK2 GENE; COPY NUMBER VARIATION; GENE DELETION; GENE INSERTION; GENETIC ANALYZER; GENETIC PROCEDURES; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MEMORIAL SLOAN KETTERING INTEGRATED MUTATION PROFILING OF ACTIONABLE CANCER TARGET; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE VARIANT; SOLID MALIGNANT NEOPLASM; TP53 GENE; TSC2 GENE; TUMOR SUPPRESSOR GENE; VHL GENE; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NEOPLASM; PROCEDURES; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 85019648284     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-017-0271-4     Document Type: Article

References (21)

1. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687-98. doi:10.1200/JCO.2013.49.7271.
2. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302-8. doi:10.1038/nature12981.
3. Rahman N. Mainstreaming genetic testing of cancer predisposition genes. Clin Med. 2014;14(4):436-9. doi:10.7861/clinmedicine.14-4-436.
4. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-7. doi:10.1073/pnas.1115052108.
5. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010;107(28):12629-33. doi:10.1073/pnas.1007983107.
6. Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012;14(4):357-66. doi:10.1016/j.jmoldx.2012.03.002.
7. Trujillano D, Weiss ME, Schneider J, Koster J, Papachristos EB, Saviouk V, et al. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. J Mol Diagn. 2015;17(2):162-70. doi:10.1016/j.jmoldx.2014.11.004.
8. Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, et al. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn. 2012;14(5):467-75. doi:10.1016/j.jmoldx.2012.03.006.
9. Cheng DT, Mitchell T, Zehir A, Shah RH, Benayed R, Syed A, et al. MSK-IMPACT: a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015. doi:10.1016/j.jmoldx.2014.12.006.
10. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-9. doi:10.1038/nbt.2514.
11. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333-9. doi:10.1093/bioinformatics/bts378.
12. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. doi:10.1093/nar/gkq603.
13. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-303. doi:10.1101/gr.107524.110.
14. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980-5. doi:10.1093/nar/gkt1113.
15. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-11.
16. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65. doi:10.1038/nature11632.
17. Tennessen JA, Bigham AW, O’Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64-9. doi:10.1126/science.1219240.
18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015. doi:10.1038/gim.2015.30.
19. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2(1):104-11.
20. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-74. doi:10.1038/gim.2013.73.
21. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161.